- Home
- TNGX vs CAAP Comparison
TNGX vs CAAP Comparison
Compare TNGX & CAAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | CAAP |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.5B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TNGX | CAAP |
|---|---|---|
| Price | $26.52 | $25.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $21.78 | ★ $26.73 |
| AVG Volume (30 Days) | ★ 3.3M | 185.9K |
| Earning Date | 05-08-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,384,000.00 | N/A |
| Revenue This Year | N/A | $5.80 |
| Revenue Next Year | N/A | $2.36 |
| P/E Ratio | ★ N/A | $26.35 |
| Revenue Growth | ★ 48.29 | N/A |
| 52 Week Low | $5.60 | $17.36 |
| 52 Week High | $34.39 | $30.50 |
Technical Indicators
Market Signals| Indicator | TNGX | CAAP |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 49.12 |
| Support Level | $19.74 | $24.78 |
| Resistance Level | $28.41 | $26.76 |
| Average True Range (ATR) | 1.75 | 0.66 |
| MACD | -0.53 | 0.04 |
| Stochastic Oscillator | 2.32 | 61.62 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.